Introduction
Approximately one-third of cases of de novo acute myeloid leukemia (AML) carry mutations in the C-terminal region of the nucleophosmin (NPM1) gene (1) (2) . AML with mutated NPM1
shows distinctive biological and clinical features, including female gender, monocytoid morphology, CD34-negativity and a unique gene expression profile (3) . These features are irrespective of whether NPM1-mutated AML carries a normal karyotype (about 85% of cases) or secondary chromosomal aberrations (about 15%), thus reinforcing the view that NPM1 mutation is a founder genetic lesion (4) . In the absence of FLT3-ITD mutations, AML with a normal karyotype and NPM1 mutation confers a significantly better prognosis than other AML cases with a normal karyotype (5) (6) (7) (8) . A recent study indicates that these prognostic considerations also apply to NPM1-mutated AML patients carrying secondary chromosomal aberrations (9) . Frameshift NPM1 mutations create a new leucine-rich sequence at the proteins C-terminus which serves as a nuclear export signal. This, accompanied by loss of tryptophan residues, is responsible for the increased nuclear export and aberrant cytoplasmic accumulation of the NPM1 leukemic mutants (10) .
NPM1 mutations were initially detected following the observation that in B5-fixed/EDTA decalcified bone marrow trephine (BMT) biopsies, NPM protein was aberrantly expressed in the cytoplasm of leukemic cells of about one-third of AML patients (1). This anomalous staining pattern is closely correlated with the presence of mutated NPM1 (10) . As BMT biopsies are not always performed at diagnosis of AML, the ability to detect cNPM on cell smears would be advantageous. We have established a technique to assess NPM expression in routine hematologic smear samples and assessed its correlation with NPM1 mutation status.
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Design and Methods
Samples
Cell lines FL18 and L428 was cultured with recommended media and OCI-AML3 (DSMZ, Braunschweig, Germany) as described elsewhere (11) . OCI-AML3 were diluted into normal whole blood at approximately 4-5x10 6 cells/mL. 
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Antibodies and immunocytochemical staining
Mouse anti-NPM antibodies NA24 (author's laboratory; DYM)(12) and Clone 376 (Dako A/S, Glostrup, Denmark) were used (1, 10, (12) (13) (14) . and Photoshop processed (16) . A Nikon E800 Eclipse microscope was used with 40x magnification.
Detection of nucleophosmin mutations
Genomic DNA was extracted from blood or bone marrow aspirate samples, and mutations within exon 12 of NPM1 detected by PCR and fragment analysis (17) . Two protocols were used; the fluorescently labeled forward 5'-(dyeD4)TTCCATACATACTTAAAACCAAGCA-3' and reverse 5'-TGGTTCCTTAACCACATTTCTTT-3' primers were used to amplify exon 12 of NPM1 (18) . Fluorescent PCR products were subjected to capillary electrophoresis on denaturing polyacrylamide gel before analyzed. The second protocol was performed with PCR, restriction enzyme detection and capillary electrophoresis (19) . The primers used were NPM1
12F 5'NED/TGTCTATGAAGTGTTGTGGTTCC-3', and NPM1 12R 5'-CTGGACAACATTTATCAAACACG-3'.
© F e r r a t a S t o r t i F o u n d a t i o n
Immunoelectron microscopy
Suspensions of FL18, L428, OCI-AML3 and leukocytes from a CLL case were fixed overnight in 2% (vol/vol) formaldehyde in 0.1 mol/l phosphate buffer. After washing samples were rapidly dehydrated in ethanol, embedded in LR White resin and processed (18) . Sections were placed on grids, incubated with NA24 (undiluted) or Clone 376 (1:80), and a secondary antibody (10nm gold particles), counterstained and examined in a Joel 1200EX transmission electron microscope (Joel UK Ltd, Welwyn Garden City, UK) at 80 kV (20) .
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Results and Discussion
The immunostaining protocol to detect NPM was optimized on smears prepared of normal blood mixed with OCI-AML3 cells, which carries the NPM1 C-terminal mutation (21) . Optimal morphological preservation and NPM antigenicity was obtained with acetone/methanol/formalin fixation and pre-treatment. This resulted in cytoplasmic NPM (cNPM) detectable in >98% of the OCI-AML3 cells as well as the nucleolus (Figure 1 ).
Immunoelectron microscopy showed positive labeling in the nucleoli of CLL leucocytes ( Figure   1A ), OCI-AML3, FL18 and L428 cells (data not shown), in line with earlier published electron microscopy results (22) . The nucleolar localization of NPM in cytological samples contrasts with previous reports that demonstrate pan-nuclear expression pattern (1, 12). The OCI-AML3 cell line did not show cNPM by immunoelectron microscopy. We postulate that this difference in localization is due to differences in sample processing, including the acetone/methanol/formalin fixative, or that the cytoplasmic NPM is non-specific. The phenomenon of alterations in staining localisation in differently processed tissue samples has been observed for other proteins, e.g. To determine whether the discrepancies between NPM1 mutation status and cNPM in the cell smears was by chance, paired smears and BMT biopsies of a further 22 AML cases were analysed. The results for the smears were as described above with positive staining in the nucleoli and minimal cytoplasmic positivity (Table 1 ). In the BMT biopsies all cells showed pan-nuclear NPM staining with the strongest signal being within the nucleolus and some cNPM ( Figure 2 ).
There was no correlation between the percentage of cNPM positive cells in cell smears and the BMT result. There were two BMT cases (Table 1 ; n=2 and n=18) where cNPM and the NPM1 mutation status did not agree. It is of note that all publications to-date that demonstrate a positive correlation between NPM1 mutations and cNPM by immunocytochemistry on BMT biopsies have used B5 fixation (1, 24) . This fixative is rarely used routinely in haematopathology with a recent report showing B5 was only used by 18% of laboratories for BMT biopsies (25) . As different fixatives are known to have different effects on tissue antigens this could explain the 2 "false negative" Bouin-fixed BMT results in the present series (25) .
Overall, for all 60 cell smears assessed, the false positive rate for cNPM compared with NPM1 genotype was 41.2% (15/36 cNPM-positive cases) and false negative rate 41.7% (10/24cNPM-negative cases). We hypothesize that the discrepancies are due to the sample type and methodological differences in processing and are not case-specific. Specifically, BMT have undergone fixation, decalcification and processing into paraffin, whereas cell smears have been air-dried and fixed immediately prior to immunocytochemical analysis. Furthermore, in smears © F e r r a t a S t o r t i F o u n d a t i o n the cell is intact and the entire cytoplasm is visible and can easily be distinguished from the nucleus (Figure 1 ). This is relevant, as a morphologic characteristic of blast cells in AML is that they have minimal cytoplasm and a high nuclear: cytoplasmic ratio. The small size of some blast cells and minimal cytoplasm is acknowledged as one of the problems encountered in the interpretation of the sub-cellular localization of NPM in BMT biopsies (24) .
We have developed a method capable of detecting cNPM in cell smears by immunocytochemistry, but the staining results bear no correlation with NPM1 mutation status.
We therefore recommend that this method not be used as a surrogate marker for NPM1
mutations. B5-fixed/EDTA decalcified BMT biopsies therefore remain the only suitable specimen for the immunocytochemical detection of cNPM. Flow cytometric methods may prove to be a useful alternative for assessing blood and bone marrow aspirate samples (26) . © F e r r a t a S t o r t i F o u n d a t i o n © F e r r a t a S t o r t i F o u n d a t i o n 
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